Heart failure remains a leading cause of hospitalization and death, and presents a
significant challenge for healthcare providers despite the advancements in its management …

Abstract Sodium–glucose cotransporter-2 (SGLT-2) inhibitors showed benefit in patients
with heart failure. In this updated meta-analysis, we evaluate the therapeutic efficacy and …

Aims Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have now been evaluated for the
treatment of heart failure in several placebo-controlled randomized controlled trials (RCTs) …

Abstract Sodium–glucose cotransporter‐2 inhibitors (SGLT2is) reduce morbidity and
mortality for heart failure (HF) patients and are recommended as cornerstones for their …

Aims We sought to conduct a meta‐analysis regarding the safety and efficacy of sodium‐
glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and …

Purpose Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have been shown in
randomized controlled trials to improve cardiovascular, metabolic, and renal outcomes in …

Aims Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to have benefit
in patients with heart failure (HF). Multiple systematic reviews and meta-analyses (SRs and …

Background Sodium-glucose co-transporter 2 (SGLT-2) inhibitors emerged as a new
groundbreaking therapy for patients with heart failure. Recent evidence showed significant …

Background We aimed to conduct this study with the goal of further clarifying the role of
sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with preexisting heart failure …

Aims Sodium-glucose co-transporter inhibitors (SGLT2i) are emerging as a new treatment
for heart failure (HF) after demonstrating favorable clinical outcomes in several randomized …